VRDN

Viridian Therapeutics Inc.

Price

$24.80

return (12m)

39.25%

p/e

-6.14

p/bv

3.59

DIVIDEND YIELD

0.00%

VRDN price

Viridian Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment VRDN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

32.34%

3 months

40.19%

1 year

39.25%

2 years

56.66%

5 years

81.95%

10 years

-79.01%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals VRDN

Valuation

P/E

-6.14

Sector -4.38

Industry -4.38

P/BV

3.59

Sector 2.02

Industry 2.02

P/Revenue (PSR)

33.41

Sector -4.40

Industry -4.40

EV/EBITDA

-13.79

Sector -263.09

Industry -263.09

EV/EBIT

-13.78

Sector -702.90

Industry -702.90

P/EBITDA

-6.41

Sector -4.39

Industry -4.39

P/EBIT

-6.40

Sector -4.73

Industry -4.73

P/Total Assets

2.17

Sector 1.49

Industry 1.49

P/Net Current Assets

3.68

Sector -11.70

Industry -11.70

P/Working Capital

2.34

Sector -3.19

Industry -3.19

EPS

-3.58

Sector -2.14

Industry -2.14

BVPS

6.13

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-42,392.86%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-42,432.14%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-58.45%

Sector -65.14%

Industry -65.14%

ROA

-35.27%

Sector -65.53%

Industry -65.53%

ROIC

-1,252.85%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

16.95

Sector 2.90

Industry 2.90

Net Debt / EBITDA

6.23

Sector -6.07

Industry -6.07

Net Debt / EBIT

6.22

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.12

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.37

Sector -0.05

Industry -0.05

Equity/Assets

0.60

Sector 0.41

Industry 0.41

Liabilities/Assets

0.40

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

88.86%

Sector -

Industry -

5Y Earnings CAGR

37.27%

Sector -

Industry -

Fundamentals VRDN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
VRDN Viridian Therapeutics Inc.	$24.80	36.94%	0.00%	-6.14	3.59	-58.45%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

VRDN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Viridian Therapeutics

Viridian Therapeutics Inc.

Average Investor10 user rating

4.0 (1 people)

United States

12 years

Founded: 2014

2014

Time since IPO - 12 years

27

Employees

Viridian Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.38 billion, with shareholders equity totaling $662.10 million.

The company employs approximately 27 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Viridian Therapeutics Inc. reported $71.12 million in revenue, generating net income of $-386.98 million.

Key financial metrics include a P/E ratio of -6.14, a price-to-book (P/B) ratio of 3.59, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker VRDN.

Market cap

$2.38 billion

Net worth

$662.10 million

$662,100,000.00

Assets

$1.10 billion

$1,097,230,000.00

Total Shares Outstanding

108.00 million

108,000,000

Average Daily Trading Volume

$2.08 million

$2,084,890.00

Sector

Health Care

Industry

Biotechnology

VRDN

VRDN revenue and profits

Financial Results VRDN

DRAG THE FRAME TO SEE MORE DATA

VRDN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Viridian Therapeutics (VRDN) today?

A cotação de Viridian Therapeutics (VRDN) hoje está em US$ 24.80, com uma variação de 39.25% em relação ao último ano. A cotação de Viridian Therapeutics (VRDN) iniciou o ano negociando na casa dos US$ 31.12 e hoje está em US$ 24.80. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Viridian Therapeutics (VRDN) e dados de ações do Ibovespa e mercados internacionais.

Quando Viridian Therapeutics (VRDN) paga dividendos?

Viridian Therapeutics (VRDN) não distribuiu dividendos no último ano.

Is Viridian Therapeutics (VRDN) a good investment?

Atualmente, Viridian Therapeutics (VRDN) está cotada a US$ 24.80, com um P/L de -6.14, representando um desvio de -685% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 39.25 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 39.25%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Viridian Therapeutics (VRDN) stock?

Investir em ações de Viridian Therapeutics (VRDN) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Viridian Therapeutics (VRDN) yield today?

A rentabilidade de Viridian Therapeutics (VRDN) foi de 32.34% no último mês, 39.25% no último ano e 81.95% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Viridian Therapeutics (VRDN) hoje, o investimento total seria de US$ 2,480.00, com base na cotação atual de US$ 24.80.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 3,453.40
Em 5 anos: US$ 4,512.36
Em 10 anos: US$ 520.55

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

VRDN

Viridian Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment VRDN

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING VRDN WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Viridian Therapeutics

Viridian Therapeutics Inc.

United States

12 years

2014

27

PROFIT X PRICE VRDN

Financial Results VRDN

VRDN cash flow

Asset, Revenue and Profit Growth - VRDN

VRDN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions